We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Centogene NV (CNTG) NPV

Sell:$0.44 Buy:$0.49 Change: $0.0189 (4.10%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:$0.44
Buy:$0.49
Change: $0.0189 (4.10%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:$0.44
Buy:$0.49
Change: $0.0189 (4.10%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.

Contact details

Address:
Am Strande 7
ROSTOCK
18055
Germany
Telephone:
+49 (381) 80113400
Website:
https://www.centogene.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CNTG
ISIN:
NL0014040206
Market cap:
$13.38 million
Shares in issue:
27.87 million
Sector:
Health Care Services
Exchange:
NASDAQ
Country:
Netherlands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Peer Schatz
    Independent Chairman of the Supervisory Board
  • Kim Stratton
    Chief Executive Officer, Managing Director
  • Andreas Busch
    Vice Chairman of the Supervisory Board
  • Jose Rios
    Chief Financial Officer - Legal & IT
  • Patrice Denefle
    Chief Scientific Officer
  • Peter Bauer
    Chief Genomic Officer and Chief Medical Officer, Managing Director, Member of the Management Board
  • Bettina Goerner
    Chief Data Officer
  • Ian Rentsch
    Chief Commercial Officer and General Manager - Pharma

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.